Business Standard

World in turmoil, domestic pharma firms target India for healthy growth

Share of India revenue in home-grown firms' consolidated turnover rising over the years

Medicines, Pharma
Premium

25 per cent of the Indian drug market is under price control, for the rest, firms can take a 10 per cent hike annually in prices

Sohini Das Mumbai
The share of the Indian market in the overall turnover of pharmaceutical (pharma) companies has risen in the past few years. There are several reasons behind this: pricing pressure in the US generics market, currency volatility in the emerging markets (EMs), and India being the only consistent geography with stable prices and demand.

A Business Standard analysis reveals how the share of the India business in the overall turnover rose steadily from 25 per cent in 2018-19 (FY19) for Sun Pharmaceutical Industries (Sun Pharma) to 33 per cent in 2021-22 (FY22). The company ranks No. 1 in the Indian market,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Nov 22 2022 | 10:38 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com